Wells Fargo (NYSE:WFC) downgraded Lockheed Martin (NYSE:LMT) to Equal Weight from Overweight and adjusted its price target to $415.00 from $406.00. According to the analysts,...
The market is waiting for the release of multiple economic statistics scheduled throughout the next two days. Currently, all eyes have turned to the Jackson Hole Symposium. The...
For the consumer, inflation losing its sharp edge was the story this week. It was a move fuelled mostly by a welcomed drop in gas prices. But for the investor, the positive...
Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Core Illumina products and services serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. GRAIL is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed for genetic analysis. Customers use its platforms to perform whole genome, de novo, exome and ribonucleic acid (RNA) sequencing, and targeted resequencing of specific gene regions and genes. The Company's BeadArray technology produces arrays that can perform many assays simultaneously. Customers use its array-based genotyping consumables for a range of analyses, including diverse species, disease-related mutations, and genetic characteristics associated with cancer.
|Average||259.38 (+35.95% Upside)|
|No. of Analysts||17|